Archive for May 1, 2013

Emergence of Avian Influenza A(H7N9) Virus Causing Severe Human Illness — China, February–April 2013

MMWR  May 1, 2013   Volume 62, Early Release   Early Release

On March 29, 2013, the ChinaCenter for Disease Control and Prevention confirmed three human infections with an avian influenza A(H7N9) virus. The cases, which were reported to the World Health Organization on April 1, occurred among adults (two in Shanghai and one in AnhuiProvince). All three patients, although not epidemiologically linked, had severe pneumonia, developed acute respiratory distress syndrome, and died from their illness. As of April 29, China had reported 126 confirmed H7N9 cases, including 24 that resulted in deaths. This report summarizes the latest H7N9 findings and recommendations for dealing with potential cases in the United States.

FULL TEXT

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm62e0501a1.htm?s_cid=mm62e0501a1_e

PDF

http://www.cdc.gov/mmwr/pdf/wk/mm62e0501.pdf

 

May 1, 2013 at 7:10 pm

Topical ganciclovir in the treatment of acute herpetic keratitis.

Clin Ophthalmol. 2010 Aug 19;4:905-12.

Tabbara KF, Al Balushi N.

Source

The Eye Center and The Eye Foundation for Research in Ophthalmology, Riyadh, Kingdom of Saudi Arabia. k.tabbara@nesma.net.sa

Abstract

Herpetic keratitis is caused by herpes simplex virus (HSV) and is a common cause of corneal blindness. Following a primary ocular herpetic infection, latency of the virus occurs, followed by subsequent recurrences of herpetic keratitis. Such recurrences may lead to structural damage of the cornea. Recurrent herpetic keratitis is a common indication for corneal transplantation. Recurrences of herpetic keratitis in the corneal graft may lead to corneal graft rejection. Several antiviral agents for HSV are available, including the thymidine analogs. Prolonged use of thymidine analogs may lead to toxicity of the ocular surface, including epithelial keratitis, corneal ulcers, follicular conjunctivitis, and punctal occlusions. Availability of topical antiviral agents that are safe and effective in the treatment and prophylaxis of herpetic keratitis is highly desirable. Ganciclovir is a potent inhibitor of members of the herpes virus family. The drug has been used systemically for the treatment of cytomegalovirus (CMV) retinitis. Its hematologic toxicity secondary to systemic administration led to its limited use in herpetic infections. On the other hand, topical ganciclovir has been shown to be as safe and effective as acyclovir in the treatment of herpetic epithelial keratitis. Furthermore, topical ganciclovir can reach therapeutic levels in the cornea and aqueous humor following topical application. Several clinical trials have shown that topical ganciclovir 0.15% ophthalmic gel is safe and effective in the treatment and prophylaxis of herpetic epithelial disease. Long-term use of ganciclovir ophthalmic gel in patients with penetrating keratoplasty following herpetic keratitis has prevented recurrences of the disease. Topical ganciclovir ophthalmic gel is well tolerated, does not cause toxic effects on the ocular surface, and does not cause hematologic abnormalities. Clinical studies have underscored the potential role of ganciclovir ophthalmic gel in the treatment and prophylaxis of herpetic epithelial keratitis. Future randomized, controlled, multicenter, prospective clinical trials are needed to assess the long-term safety and efficacy of topical ganciclovir in the treatment and prevention of herpetic keratitis and uveitis

PDF

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925452/pdf/opth-4-905.pdf

 

May 1, 2013 at 7:08 pm

Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Future Microbiol. 2011 Aug;6(8):877-907.

Al-Dujaili LJ, Clerkin PP, Clement C, McFerrin HE, Bhattacharjee PS, Varnell ED, Kaufman HE, Hill JM.

Source

Department of Ophthalmology, Louisiana State University Health Sciences Center, New Orleans, USA.

Abstract

Most humans are infected with herpes simplex virus (HSV) type 1 in early childhood and remain latently infected throughout life. While most individuals have mild or no symptoms, some will develop destructive HSV keratitis. Ocular infection with HSV-1 and its associated sequelae account for the majority of corneal blindness in industrialized nations. Neuronal latency in the peripheral ganglia is established when transcription of the viral genome is repressed (silenced) except for the latency-associated transcripts and microRNAs. The functions of latency-associated transcripts have been investigated since 1987. Roles have been suggested relating to reactivation, establishment of latency, neuronal protection, antiapoptosis, apoptosis, virulence and asymptomatic shedding. Here, we review HSV-1 latent infections, reactivation, recurrent disease and antiviral therapies for the ocular HSV diseases.

PDF

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403814/pdf/nihms-384464.pdf

May 1, 2013 at 7:07 pm

Progress in introduction of pneumococcal conjugate vaccine – worldwide, 2000-2012.

MMWR Morb Mortal Wkly Rep. 2013 Apr 26;62(16):308-11.

Centers for Disease Control and Prevention (CDC).

Abstract

Pneumococcal conjugate vaccines (PCVs) are safe and effective for reducing illness and deaths caused by Streptococcus pneumoniae. Recommendations for PCV use from the World Health Organization (WHO) and funding from the GAVI Alliance have resulted in an increase in PCV introductions into national immunization programs, especially in lower-income countries. Additionally, new formulations that cover more serotypes commonly causing disease in lower- and middle-income countries have become available. This report uses WHO data from 2000-2012, stratified by country disease burden characteristics and World Bank country income groups, to describe global progress in PCV introduction. As of December 2012, a total of 86 (44%) WHO member states have added PCV to the routine infant immunization schedule of their national immunization programs; among those, 23 have introduced PCV with GAVI Alliance support. PCV introduction among WHO member states was most common in the Americas Region (60% of member states), followed by the Eastern Mediterranean Region (50%), European Region (49%), African Region (41%), and Western Pacific Region (33%); none of 11 WHO member states in the South-East Asia Region have introduced PCV. Proportions of low- and middle-income countries with PCV introductions were similar. The proportion of the world’s birth cohort living in countries with PCV in national immunization programs increased from 1% in 2000 to 31% in 2012. These findings suggest that efforts to increase PCV introduction and use globally are succeeding; however, gaps in PCV use remain in Asia and countries with large birth cohorts, where concerted efforts should be focused.

FULL TEXT

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6216a4.htm

PDF

http://www.cdc.gov/mmwr/pdf/wk/mm6216.pdf

May 1, 2013 at 7:06 pm

Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group.

N Engl J Med. 1998 Jul 30;339(5):300-6.

Abstract

BACKGROUND:

Long-term treatment with antiviral agents has been shown to prevent recurrences of genital and orofacial herpes simplex virus (HSV) disease, but it is uncertain whether prophylactic treatment can prevent recurrences of ocular HSV disease.

METHODS:

We randomly assigned 703 immunocompetent patients who had had ocular HSV disease within the preceding year to receive 400 mg of acyclovir or placebo orally twice daily. The study outcomes were the rates of development of ocular or nonocular HSV disease during a 12-month treatment period and a 6-month observation period.

RESULTS:

The cumulative probability of a recurrence of any type of ocular HSV disease during the 12-month treatment period was 19 percent in the acyclovir group and 32 percent in the placebo group (P<0.001). Among the 337 patients with a history of stromal keratitis, the most common serious form of ocular HSV disease, the cumulative probability of recurrent stromal keratitis was 14 percent in the acyclovir group and 28 percent in the placebo group (P=0.005). The cumulative probability of a recurrence of nonocular (primarily orofacial) HSV disease was also lower in the acyclovir group than in the placebo group (19 percent vs. 36 percent, P<0.001). There was no rebound in the rate of HSV disease in the six months after treatment with acyclovir was stopped.

CONCLUSIONS:

After the resolution of ocular HSV disease, 12 months of treatment with acyclovir reduces the rate of recurrent ocular HSV disease and orofacial HSV disease. Long-term antiviral prophylaxis is most important for patients with a history of HSV stromal keratitis, since it can prevent additional episodes and potential loss of vision.

PDF

http://www.nejm.org/doi/pdf/10.1056/NEJM199807303390503

 

Comment in

Editorial

Acyclovir for recurrent herpes simplex virus ocular disease. [N Engl J Med. 1998]

http://www.nejm.org/doi/pdf/10.1056/NEJM199807303390510

 

May 1, 2013 at 7:03 pm


Calendar

May 2013
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Posts by Month

Posts by Category